The global market for Hepatitis E Diagnostic Tests was estimated at US$55.4 Million in 2024 and is projected to reach US$67.8 Million by 2030, growing at a CAGR of 3.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Hepatitis E Diagnostic Tests market.
Segments: Type (ELISA HEV IGM Tests Type, ELISA HEV IGG Tests Type, Rapid Diagnostics Tests Type, Polymerase Chain Reaction Type); End-Use (Hospitals End-Use, Diagnostics Laboratories End-Use, Blood Banks End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Hepatitis E Diagnostic Tests Market - Key Trends & Drivers Summarized
Why Is Hepatitis E Diagnosis Gaining Global Attention?
Hepatitis E, a liver infection caused by the hepatitis E virus (HEV), is becoming an increasing public health concern, particularly in developing regions with limited access to clean water and sanitation. The disease primarily spreads through contaminated water sources, making it a significant challenge in countries with poor infrastructure. Diagnostic tests play a crucial role in detecting HEV infections, facilitating timely treatment, and preventing outbreaks. The growing prevalence of hepatitis E in both endemic and non-endemic regions has heightened the demand for accurate and rapid diagnostic solutions. Governments and healthcare organizations are investing in screening programs to mitigate the spread of HEV, driving the expansion of the hepatitis E diagnostic tests market.How Are Technological Innovations Improving Hepatitis E Diagnostics?
The hepatitis E diagnostic market is witnessing rapid technological advancements, with improvements in serological assays, polymerase chain reaction (PCR) techniques, and point-of-care testing solutions. The development of enzyme-linked immunosorbent assays (ELISA) has enhanced the accuracy and efficiency of detecting HEV antibodies, allowing for early diagnosis and disease monitoring. Additionally, the introduction of molecular diagnostic techniques, such as real-time PCR, has enabled precise identification of HEV RNA, aiding in the differentiation of acute and chronic infections. The emergence of rapid test kits is further improving access to hepatitis E diagnostics, particularly in resource-limited settings. These innovations are enhancing the reliability and accessibility of hepatitis E testing, contributing to improved disease control efforts.Why Is the Demand for Hepatitis E Diagnostic Tests Increasing?
The rising incidence of hepatitis E infections, increasing global travel, and growing awareness about viral hepatitis have fueled the demand for hepatitis E diagnostic tests. Governments and healthcare agencies are implementing screening programs in high-risk populations, such as pregnant women and immunocompromised individuals, to prevent complications associated with HEV infections. The expansion of point-of-care diagnostics in rural areas has also contributed to improved disease detection and management. Additionally, advancements in diagnostic automation are reducing turnaround times, enabling faster decision-making in clinical settings. As global health organizations prioritize hepatitis prevention and control, the demand for HEV diagnostic solutions is expected to grow significantly.What Are the Key Factors Driving the Growth of the Hepatitis E Diagnostic Tests Market?
The growth in the hepatitis E diagnostic tests market is driven by increasing disease prevalence, advancements in diagnostic technologies, and government initiatives aimed at improving viral hepatitis surveillance. The expansion of healthcare infrastructure in developing countries is also facilitating greater access to hepatitis testing. Additionally, the rising investment in research and development for faster and more accurate diagnostic solutions is contributing to market growth. As public health strategies focus on early detection and prevention of viral hepatitis, the hepatitis E diagnostic tests market is poised for substantial expansion.Report Scope
The report analyzes the Hepatitis E Diagnostic Tests market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type (ELISA HEV IGM Tests Type, ELISA HEV IGG Tests Type, Rapid Diagnostics Tests Type, Polymerase Chain Reaction Type); End-Use (Hospitals End-Use, Diagnostics Laboratories End-Use, Blood Banks End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the ELISA HEV IGM Tests Type segment, which is expected to reach US$29.6 Million by 2030 with a CAGR of a 4.8%. The ELISA HEV IGG Tests Type segment is also set to grow at 2.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $15.1 Million in 2024, and China, forecasted to grow at an impressive 6.6% CAGR to reach $13.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Hepatitis E Diagnostic Tests Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hepatitis E Diagnostic Tests Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Hepatitis E Diagnostic Tests Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Altona Diagnostics GmbH, Beijing Beier Bioengineering Co., Ltd., Beijing Zhongjian Antai Diagnosis Technology Co., Ltd., CTK Biotech, Inc., Dia.Pro Diagnostic Bioprobes s.r.l and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 42 Featured):
- Altona Diagnostics GmbH
- Beijing Beier Bioengineering Co., Ltd.
- Beijing Zhongjian Antai Diagnosis Technology Co., Ltd.
- CTK Biotech, Inc.
- Dia.Pro Diagnostic Bioprobes s.r.l
- DiaSorin S.p.A.
- ELITechGroup
- Eurofins Viracor
- F. Hoffmann-La Roche Ltd
- Fortress Diagnostics
- GenScript Biotech Corporation
- Guangzhou Wondfo Biotech Co., Ltd.
- Healgen Scientific
- Jiangsu Macro micro-test Medical Technology
- Medsource Ozone Biomedicals Pvt. Ltd.
- Mikrogen GmbH
- MP Biomedicals
- PerkinElmer, Inc.
- Primerdesign Ltd
- Wantai BioPharm
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Altona Diagnostics GmbH
- Beijing Beier Bioengineering Co., Ltd.
- Beijing Zhongjian Antai Diagnosis Technology Co., Ltd.
- CTK Biotech, Inc.
- Dia.Pro Diagnostic Bioprobes s.r.l
- DiaSorin S.p.A.
- ELITechGroup
- Eurofins Viracor
- F. Hoffmann-La Roche Ltd
- Fortress Diagnostics
- GenScript Biotech Corporation
- Guangzhou Wondfo Biotech Co., Ltd.
- Healgen Scientific
- Jiangsu Macro micro-test Medical Technology
- Medsource Ozone Biomedicals Pvt. Ltd.
- Mikrogen GmbH
- MP Biomedicals
- PerkinElmer, Inc.
- Primerdesign Ltd
- Wantai BioPharm
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 285 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 55.4 Million |
| Forecasted Market Value ( USD | $ 67.8 Million |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
